This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst
Portfolio Pulse from Priya Nigam
Teleflex Inc (NYSE:TFX) has been upgraded by Piper Sandler analyst Matt O’Brien from Neutral to Overweight, with a price target increase from $205 to $245. The upgrade is driven by expected improvements in UroLift sales, regulatory issues faced by competitor Getinge, and strong growth potential for the Barrigel product.
July 01, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teleflex Inc (NYSE:TFX) has been upgraded by Piper Sandler analyst Matt O’Brien from Neutral to Overweight, with a price target increase from $205 to $245. The upgrade is driven by expected improvements in UroLift sales, regulatory issues faced by competitor Getinge, and strong growth potential for the Barrigel product.
The upgrade by Piper Sandler and the increased price target are significant positive signals for TFX. The expected recovery in UroLift sales, regulatory issues faced by competitor Getinge, and strong growth potential for the Barrigel product are all likely to drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100